Deadline: February 20, 2022
The Mark Wainberg Fellowship Programme, an initiative of the IAS Educational Fund, is aimed at contributing to improving the quality of HIV service delivery in resource-limited settings by providing two-year fellowships to clinicians from sub-Saharan Africa, who will spend one year in Europe and one year in Africa at clinical institutions. The program will offer in-depth training for clinicians committed to careers in HIV clinical service delivery in sub-Saharan Africa with the aim of strengthening access to high-quality services for sub-Saharan Africa populations, with a client-centered service delivery approach.
Many African countries face an unmet need in the training of medical practitioners who want to become specialized in HIV. HIV medicine sub-specialization is not attractive for many young healthcare professionals, which is in sharp contrast to the need for such specialized personnel and leadership in the hardest-hit countries in sub-Saharan Africa.
To be eligible for the Mark Wainberg Fellowship Programme, candidates should meet the following requirements:
- Terminal research degree as a medical doctor (or equivalent)
- Minimum of two years’ clinical experience
- Currently working in sub-Saharan Africa
- Commitment to become a specialist in HIV
- English, French or Portuguese speaking.
The fellows will be selected with a view to their potential of functioning as a multiplier and disseminate the knowledge learned (for example, towards other physicians, nurses, community healthcare providers) to further broaden the impact of the programme. At the end of their fellowship, the fellows should have skills that enable them to mentor and train other fellows.
Please note that fellows will receive a living allowance for the duration of the Mark Wainberg Fellowship Programme; applicants should ensure they are financially able to enrol in the 2-year programme before accepting the fellowship.
Mark Wainberg was a pioneer for HIV research, advocacy and scientific advancement. He was the President of the International AIDS Society (1998-2000) and is widely known for his part in the 1989 discovery that the drug 3TC could be used to treat HIV infection.